$RACC
Research Alliance Corporation III Class A Ordinary Shares
XNAS•Health Care•Pharmaceutical Preparations
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateResearch Alliance Corporation III Class A Ordinary Shares
XNAS•Health Care•Pharmaceutical Preparations
Why is RACC down today? It is at $10.02 (-1.09%), and our scanner flagged it 6 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment RACC spikes, and full due diligence on RACC — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $RACC 6 times in the last 30 days. Create a free account to track $RACC, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on RACC from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for RACC today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystClinical / FDA update, from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedOct 7, 2026 · 19 days agoAcross every filing on file, supply equal to 1865% of the tradeable float is in play - 1865% has already been sold.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
7,500,000 new shares · About $750K in size · Priced at $10/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Hammond Matthew Officer | Acquired (grant/award) | +275K 3.0% of company | n/a | 275K | $2.8M at $10.00 | May 21, 26 |
Research Alliance Holdings Iii Llc /Cayman Director | Acquired (grant/award) | +275K 3.0% of company | n/a | 275K | $2.8M at $10.00 | May 21, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on RACC from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for RACC today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
RACC last traded at $10.02, down 1.09% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The RACC Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged RACC 6 times in the last 30 days.
RACC (Research Alliance Corporation III Class A Ordinary Shares) trades on XNAS, with a market cap of about $92M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge RACC for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$RACC discussion
Sign in to ask a question or join the discussion.